m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02829)
Name
R348
Status
Terminated
Structure
Formula
C8H11N
InChI
1S/C8H11N/c1-3-8-6-9-5-4-7(8)2/h4-6H,3H2,1-2H3
InChIKey
JDQNYWYMNFRKNQ-UHFFFAOYSA-N
PubChem CID
68254
TTD Drug ID
D01XEQ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Janus kinase 3 (JAK-3)
Wilms tumor 1-associating protein (WTAP)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Janus kinase 3 (JAK-3) is a therapeutic target for R348. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of R348 through regulating the expression of Janus kinase 3 (JAK-3). [1], [2]
References
Ref 1 Transcriptome-Wide High-Throughput m6A Sequencing of Differential m6A Methylation Patterns in the Human Rheumatoid Arthritis Fibroblast-Like Synoviocytes Cell Line MH7A. J Inflamm Res. 2021 Feb 25;14:575-586. doi: 10.2147/JIR.S296006. eCollection 2021.
Ref 2 Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood. 2002 Jan 15;99(2):680-9. doi: 10.1182/blood.v99.2.680.